New York, NY -- (SBWIRE) -- 03/03/2017 -- According to the centers for disease control and prevention (CDC), out of total population 6.7% of the U.S. adults are diagnosed with ulcers. Also there are 51 million of the U.S. population that visits emergency departments for diagnosis of digestive system diseases. Increasing incidence of digestive diseases and the rising aging population globally are factors that are leading to growth of digestive distress treatment market globally. High prevalence of gastroparesis attributed to diabetes or unknown cause has created an incremental opportunity for digestive treatment market over forecast period. Development of novel products such as the domperidone drug for the treatment of gastric disorder is expected to create market opportunities for digestive problem treatment market over the forecast period. Also government and companies' initiatives for better understanding efficacy of these drugs and digestive problem treatments is likely to drive the growth of digestive distress treatment market over forecast period. However digestive distress treatment market has some restraints such as lack of clinical evidence for improvement of prescription drugs and less number of effective clinical trials is expected to hinder the growth of the digestive distress treatment market.

The rise in the incidence of digestive diseases and digestive disorders is expected to boost the digestive distress treatment market over the forecast period. Also the implementation of healthier lifestyles by consumers will boost the demand for digestive problem treatment products. In addition to better awareness among the general population, educating each patient about their treatment and digestive disease treatments is expected to drive the digestive distress treatment market during the forecast period.

Geographically the digestive distress treatment market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and MEA region.

North America followed by Europe is dominating the digestive problem treatment market owing to high incidence of digestive disease, ulcers and irritable bowel syndrome in these regions. According to the Centers for Disease Control and Prevention (CDC), in 2016 there are total 15.9 million of people in the U.S. that are diagnosed with an ulcer. In Asia Pacific region the digestive problem treatment market is expected to register substantial growth owing to rising geriatric population in this region and growing awareness among general population regarding the significance of the digestive problem treatments, in turn, is expected to further fuel the digestive problem treatment market growth over the forecast period. Moreover, the digestive problem treatment market is expected to register significant growth in the near future due to factors such as increasing incidence of digestive disease and sedentary lifestyle.

Some of the companies in the Digestive Problem Treatment market are Mylan N.V. Takeda Pharmaceuticals Company Ltd., Elan Pharmaceuticals, Novartis AG, Eli Lilly and Company and others

Browse Full Report summary and to request sample report and table of content@ http://www.persistencemarketresearch.com/market-research/digestive-distress-treatment-market.asp